Celgene Co. (NASDAQ:CELG) Shares Purchased by DekaBank Deutsche Girozentrale

Share on StockTwits

DekaBank Deutsche Girozentrale lifted its holdings in Celgene Co. (NASDAQ:CELG) by 51.1% in the second quarter, Holdings Channel reports. The firm owned 1,047,470 shares of the biopharmaceutical company’s stock after buying an additional 354,051 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Celgene were worth $96,921,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Oregon Public Employees Retirement Fund raised its stake in shares of Celgene by 4.6% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 273,716 shares of the biopharmaceutical company’s stock valued at $25,302,000 after buying an additional 12,071 shares during the last quarter. Capital Management Corp VA purchased a new position in shares of Celgene during the 1st quarter valued at about $10,955,000. Gilman Hill Asset Management LLC raised its stake in shares of Celgene by 18.6% during the 2nd quarter. Gilman Hill Asset Management LLC now owns 7,416 shares of the biopharmaceutical company’s stock valued at $686,000 after buying an additional 1,165 shares during the last quarter. Canyon Capital Advisors LLC purchased a new position in shares of Celgene during the 1st quarter valued at about $119,226,000. Finally, Ruffer LLP purchased a new position in shares of Celgene during the 1st quarter valued at about $226,613,000. 74.19% of the stock is owned by hedge funds and other institutional investors.

Shares of Celgene stock opened at $94.20 on Wednesday. The company has a current ratio of 3.44, a quick ratio of 3.32 and a debt-to-equity ratio of 1.97. Celgene Co. has a twelve month low of $58.59 and a twelve month high of $98.97. The company has a 50-day simple moving average of $92.75. The stock has a market cap of $66.70 billion, a price-to-earnings ratio of 12.38, a PEG ratio of 0.44 and a beta of 1.46.

Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.17. Celgene had a return on equity of 89.93% and a net margin of 32.24%. The firm had revenue of $4.40 billion during the quarter, compared to analyst estimates of $4.22 billion. During the same quarter in the previous year, the business earned $2.16 EPS. Celgene’s revenue for the quarter was up 15.4% compared to the same quarter last year. Sell-side analysts anticipate that Celgene Co. will post 9.96 earnings per share for the current fiscal year.

A number of research firms have weighed in on CELG. Barclays lowered Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 price objective for the company. in a research note on Friday, May 3rd. Cowen reiterated a “hold” rating and set a $102.00 price objective on shares of Celgene in a research note on Tuesday, July 30th. Zacks Investment Research upgraded Celgene from a “sell” rating to a “hold” rating and set a $94.00 price objective for the company in a research note on Tuesday, July 23rd. Mizuho reiterated a “buy” rating and set a $103.00 price objective on shares of Celgene in a research note on Wednesday, July 3rd. Finally, ValuEngine lowered Celgene from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 1st. Two research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $94.81.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Read More: The basics of gap trading strategies

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Coherent  PT Raised to $175.00
Coherent PT Raised to $175.00
BidaskClub Upgrades E*TRADE Financial  to Hold
BidaskClub Upgrades E*TRADE Financial to Hold
CME Group  Now Covered by Oppenheimer
CME Group Now Covered by Oppenheimer
Civista Bancshares  Upgraded to Hold at BidaskClub
Civista Bancshares Upgraded to Hold at BidaskClub
Cohu  Stock Rating Upgraded by BidaskClub
Cohu Stock Rating Upgraded by BidaskClub
Cognizant Technology Solutions  Downgraded by ValuEngine to Sell
Cognizant Technology Solutions Downgraded by ValuEngine to Sell


© 2006-2019 Ticker Report